Biotech company Innate Therapeutics is seeking to raise seven and a half million dollars through the issue of 15 million shares at 50 cents each.
The company needs the money to fund the phase two trial of a drug which can modify the body's immune responses.
Innate Therapeutics chief executive Simon Wilkinson talks about the new drug and how the company plan to raise the revenue.